Bausch + Lomb Corporation (FRA:S2L)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.07B +19.7% |
| Revenue (ttm) | 4.52B +7.8% |
| Net Income | -189.94M |
| EPS | -0.54 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 14.50 |
| Previous Close | 14.20 |
| Day's Range | 14.50 - 14.70 |
| 52-Week Range | 11.40 - 15.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali... [Read more]
Financial Performance
In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Bausch + Lomb launches EyeGility Inserter in U.S.
Bausch + Lomb (BLCO) announced the U.S. launch of the EyeGility Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic…
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint
Bausch + Lomb (BLCO) Corporation announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline result...
Bausch + Lomb introduces Orphia AI-powered digital health platform
Bausch + Lomb (BLCO) announced the creation of Orphia, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools…
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today an...
Bausch + Lomb price target raised to $21 from $19 at Citi
Citi raised the firm’s price target on Bausch + Lomb (BLCO) to $21 from $19 and keeps a Buy rating on the shares. For Q2 earnings season, given “the skittish…
Bausch + Lomb price target raised to $17 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Bausch + Lomb (BLCO) to $17 from $16 and keeps an In Line rating on the shares. The firm’s Q2 preview for…
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarte...
Bausch + Lomb announces new findings from third State of Dry Eye survey
Bausch + Lomb (BLCO) announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of…
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings f...
Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy focused on operational reliability, innovation, and financial excellence, targeting 5%-7% annual growth and significant margin expansion by 2028. Key innovations like Project Halo and ELIOS are set to drive future growth, with a robust pipeline and disciplined capital allocation supporting long-term market leadership.
Bausch + Lomb Transcript: R&D Day 2026
Two major contact lens innovations are advancing: Project Halo, a bioactive daily lens with HA for superior comfort, targets a 2028 U.S. launch, while a differentiated myopia control lens for children is set for 2029. Both leverage efficient manufacturing and aim to expand market share.
Bausch + Lomb Slides: FY 2026
Bausch + Lomb has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 1, 2026.
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election o...
Bausch + Lomb Transcript: AGM 2026
The meeting confirmed a quorum and addressed four proposals, including director elections, executive compensation, and auditor appointment, with all voted proposals approved. No shareholder questions were received, and final results will be disclosed in a Form 8-K.
Bausch + Lomb announces U.S. launch of PreserVision AREDS3
Bausch + Lomb (BLCO) announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of…
Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe
Bausch + Lomb (BLCO) Corporatio announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite Vision Enhancement System. “The launch of Bi-Blade+ is the la...
Bausch + Lomb Announces Second R&D “Teach-in” Webinar
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second eve...
Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Bausch + Lomb (BLCO) to $16 from $17 and keeps an In Line rating on the shares. Published first…
Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Bausch + Lomb (BLCO) to $16 from $18 and keeps a Hold rating on the shares.
Bausch + Lomb price target lowered to C$19 from C$21 at Citi
Citi lowered the firm’s price target on Bausch + Lomb (BLCO) to C$19 from C$21 and keeps a Buy rating on the shares.
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will d...